---
title: "STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer"
description: "A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer."
author: "Adam Feuerstein"
section: health
published: 2026-10-29T13:33:08.086434+00:00
canonical: https://valorandventures.media/article/a3616410-d3f8-49c5-a02d-ddd13e971786
publisher: "Valor & Ventures Media"
source: "STAT News"
source_url: https://www.statnews.com/2026/10/26/merck-kelun-sac-tmt-endometrial-cancer-study-esmo-2026/?utm_campaign=rss
access: free
---

# STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

*A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer.*

## Executive Summary

A collaborative late-stage oncology initiative between American pharmaceutical giant Merck and China-based Kelun-Biotech has delivered a meaningful survival outcome in clinical testing, according to reporting by STAT News. Results from a pivotal Phase 3 study demonstrate that the joint development program's targeted antibody-drug conjugate lowered the risk of patient death by one-third among individuals diagnosed with advanced endometrial cancer. The clinical milestone marks a crucial step forward for both pharmaceutical enterprises as they evaluate novel therapeutic options for difficult-to-treat gynecologic malignancies. The clinical data reported by the outlet provides critical validation for the investigational candidate in a disease setting that has traditionally posed steep therapeutic obstacles. In late-stage cancer research, Phase 3 trials serve as the definitive evaluation hurdle required to confirm both clinical efficacy and safety profiles before sponsors can pursue formal regulatory review and eventual commercial deployment. Achieving a one-third reduction in mortality risk within an advanced-stage cohort satisfies one of the most rigorous clinical endpoints evaluated by medical researchers and drug regulators alike. The therapeutic candidate belongs to the expanding class of antibody-drug conjugates, a targeted modality that has attracted significant attention and capital across the biopharmaceutical landscape. Unlike conventional systemic interventions that affect both healthy and diseased tissue, antibody-drug conjugates are designed to seek out specific molecular targets on cancer cells and release a targeted therapeutic payload directly to the tumor site. The successful readout in advanced endometrial cancer illustrates the ongoing shift within the oncology sector toward precision interventions capable of improving survival outcomes while aiming to spare unaffected tissue. From a commercial perspective, the development underscores the growing importance of global collaborative models in modern drug development. By partnering with China-based Kelun-Biotech, Merck has effectively diversified its oncology pipeline through targeted cross-border licensing. Multinational pharmaceutical companies increasingly depend on external discovery platforms to feed their late-stage pipelines, and this milestone reinforces how cross-border biopharma alliances can translate initial scientific agreements into tangible, late-stage clinical progress despite an intricate global business environment. For business executives, clinical leaders, and veterans of the life-sciences sector, this achievement illustrates the critical value of disciplined strategic execution and cross-border innovation. Transforming collaborative discovery into demonstrable survival advantages requires patient capital allocation, rigorous regulatory alignment, and seamless operational coordination between international partners. As enterprise leaders evaluate future investments in specialized healthcare and advanced biotechnology, this development highlights how targeted external alliances can deliver measurable progress against high-impact medical challenges.

## Article

---
Adam Feuerstein · STAT News · Photo: Adobe

---

Originally published by STAT News: https://www.statnews.com/2026/10/26/merck-kelun-sac-tmt-endometrial-cancer-study-esmo-2026/?utm_campaign=rss